The oral tyrosine kinase inhibitor pyrotinib is well tolerated and shows promising antitumor activity in people with HER2-mutated non-small-cell lung cancer, phase 2 study data show.
Gary Lyman discusses the effects of the coronavirus pandemic on various aspects of oncology clinical trials, from accrual to analysis, and highlights the need for robust research on COVID-19 and cancer.
A large UK study using the OpenSAFELY analytics platform has found that people with cancer, particularly those with hematologic malignancies, may have an elevated risk for COVID-19-related death.
Treatment with immune checkpoint inhibitors may increase the risk for poor outcomes among patients with cancer and comorbid SARS-CoV-2 infection, indicate data from New York City in the USA.
The addition of capecitabine to trastuzumab emtansine does not improve the clinical outcomes of patients with previously treated HER2-positive metastatic breast cancer, indicates the phase 1/2 TRAXHER2 study.
The oral tyrosine kinase inhibitor pyrotinib is well tolerated and shows promising antitumor activity in people with HER2-mutated non-small-cell lung cancer, phase 2 study data show.
More information about these consensus recommendations available here
Meet the Editorial Board
Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.
Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance
Register today and receive updates directly to your inbox! Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology. Already registered? Log in now to unlock your access.
